Levothyroxine Medication is Associated with Adiposity Independent of TSH

Abstract

Aim:

In euthyroidism, higher TSH levels are weakly associated with increased BMI. Furthermore, a considerable number of patients complain of weight gain during thyroid hormone replacement after thyroidectomy. We therefore investigated the association between levothyroxine medication and BMI in a large cross-sectional study group.

Methods:

We included euthyroid participants from the MeSyBePo study group (TSH between 0.3 and 4.5 μU/ml) that did not take thyreostatic drugs. Linear regression analyses were performed to address the association between levothyroxine medication and obesity. Additionally, pairs matched by sex, age and TSH but discordant in levothyroxine medication were compared.

Results:

1 663 subjects (569 males) were eligible for inclusion. 151 participants were taking levothyroxine. Adjusted for sex and age both TSH (standardised beta 0.1, p<0.001) and levothyroxine medication (standardised beta 0.05, p=0.03) were significantly associated with BMI. There was no significant interaction between TSH and levothyroxine medication with respect to BMI. Further adjustment for smoking and the restriction to those subjects with normal glucose metabolism (947 participants (314 males, 82 on levothyroxine medication) did not alter the result. In matched pair analysis (133 pairs), BMI was significantly increased in subjects taking levothyroxine compared to controls.

Conclusion:

Independently from TSH, levothyroxine medication was associated with a higher BMI. The mechanisms, however, responsible for this association need to be elucidated.

Key words

obesity - hormones - thyroid

• References

• 1 Eckel RH, York DA, Rossner S et al. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 2004; 110: 2968-2975
• 2 Silva JE. The thermogenic effect of thyroid hormone and its clinical implications. Ann Intern Med 2003; 139: 205-213
• 3 Goran MI. Energy metabolism and obesity. Med Clin North Am 2000; 84: 347-362
• 4 Hoogwerf BJ, Nuttall FQ. Long-term weight regulation in treated hyperthyroid and hypothyroid subjects. Am J Med 1984; 76: 963-970
• 5 Baron DN. Estimation of the basal metabolic rate in the diagnosis of thyroid disease. Proc R Soc Med 1959; 52: 523-525
• 6 Tzotzas T, Krassas GE, Konstantinidis T et al. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000; 10: 803-808
• 7 Tagliaferri M, Berselli ME, Calo G et al. Subclinical hypothyroidism in obese patients: relation to resting energy expenditure, serum leptin, body composition, and lipid profile. Obes Res 2001; 9: 196-201
• 8 Gjedde S, Vestergaard ET, Gormsen LC et al. Serum ghrelin levels are increased in hypothyroid patients and become normalized by L-thyroxine treatment. J Clin Endocrinol Metab 2008; 93: 2277-2280
• 9 Knudsen N, Laurberg P, Rasmussen LB et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005; 90: 4019-4024
• 10 Nyrnes A, Jorde R, Sundsfjord J. Serum TSH is positively associated with BMI. Int J Obes (Lond) 2006; 30: 100-105
• 11 Ruhla S, Weickert MO, Arafat AM et al. A high normal TSH is associated with the metabolic syndrome. Clin Endocrinol (Oxf) 2010; 72: 696-701
• 12 al Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab 1997; 82: 1118-1125
• 13 Karmisholt J, Andersen S, Laurberg P. Weight loss after therapy of hypothyroidism is mainly caused by excretion of excess body water associated with myxoedema. J Clin Endocrinol Metab 2011; 96: E99-E103
• 14 Eliakim A, Barzilai M, Wolach B et al. Should we treat elevated thyroid stimulating hormone levels in obese children and adolescents?. Int J Pediatr Obes 2006; 1: 217-221
• 15 Lomenick JP, El Sayyid M, Smith WJ. Effect of levo-thyroxine treatment on weight and body mass index in children with acquired hypothyroidism. J Pediatr 2008; 152: 96-100
• 16 Tigas S, Idiculla J, Beckett G et al. Is excessive weight gain after ablative treatment of hyperthyroidism due to inadequate thyroid hormone therapy?. Thyroid 2000; 10: 1107-1111
• 17 Dale J, Daykin J, Holder R et al. Weight gain following treatment of hyperthyroidism. Clin Endocrinol (Oxf) 2001; 55: 233-239
• 18 Brunova J, Bruna J, Joubert G et al. Weight gain in patients after therapy for hyperthyroidism. S Afr Med J 2003; 93: 529-531
• 19 Wacholder S, Silverman DT, McLaughlin JK et al. Selection of controls in case-control studies. III. Design options. Am J Epidemiol 1992; 135: 1042-1050
• 20 Oppenheimer JH, Schwartz HL, Lane JT et al. Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. J Clin Invest 1991; 87: 125-132
• 21 Andersen S, Bruun NH, Pedersen KM et al. Biologic variation is important for interpretation of thyroid function tests. Thyroid 2003; 13: 1069-1078
• 22 Gullo D, Latina A, Frasca F et al. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS One 2011; 6: e22552
• 23 Berkenstam A, Kristensen J, Mellstrom K et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2008; 105: 663-667